Tourmaline Bio Announces Formation of Cardiovascular Scientific Advisory Board
Tourmaline Bio, Inc. (NASDAQ: TRML) has announced the formation of its Cardiovascular Scientific Advisory Board (CV SAB). This board of leading experts will provide strategic guidance for the development of pacibekitug, Tourmaline's treatment for cardiovascular diseases. The CV SAB is expected to support Tourmaline as it advances towards potential Phase 3 clinical trial readiness in 2025.
The advisory board comprises academic and industry veterans with extensive experience in cardiovascular medicine, clinical trial design, and therapeutic innovation. Their expertise will be important in shaping the strategic direction of Tourmaline's cardiovascular program, including the ongoing TRANQUILITY Phase 2 clinical trial, for which topline data is expected in the first half of 2025.
Tourmaline Bio, Inc. (NASDAQ: TRML) ha annunciato la formazione del suo Comitato Consultivo Scientifico Cardiovascolare (CV SAB). Questo comitato di esperti di primo piano fornirà orientamenti strategici per lo sviluppo di pacibekitug, il trattamento di Tourmaline per le malattie cardiovascolari. Si prevede che il CV SAB sosterrà Tourmaline mentre progredisce verso una potenziale prontezza per la sperimentazione clinica di Fase 3 nel 2025.
Il comitato consultivo è composto da esperti accademici e dell'industria con una vasta esperienza nella medicina cardiovascolare, nella progettazione di trial clinici e nell'innovazione terapeutica. La loro competenza sarà fondamentale nel delineare la direzione strategica del programma cardiovascolare di Tourmaline, incluso l'attuale trial clinico di Fase 2 TRANQUILITY, per il quale ci si aspetta che i dati preliminari vengano rilasciati nella prima metà del 2025.
Tourmaline Bio, Inc. (NASDAQ: TRML) ha anunciado la formación de su Comité Asesor Científico Cardiovascular (CV SAB). Este comité de expertos destacados proporcionará orientación estratégica para el desarrollo de pacibekitug, el tratamiento de Tourmaline para las enfermedades cardiovasculares. Se espera que el CV SAB apoye a Tourmaline mientras avanza hacia una preparación para el ensayo clínico de Fase 3 en 2025.
El comité asesor está compuesto por veteranos académicos e industriales con una amplia experiencia en medicina cardiovascular, diseño de ensayos clínicos e innovación terapéutica. Su experiencia será importante para dar forma a la dirección estratégica del programa cardiovascular de Tourmaline, incluido el actual ensayo clínico de Fase 2 TRANQUILITY, para el cual se esperan datos preliminares en la primera mitad de 2025.
투말린 바이오 주식회사 (NASDAQ: TRML)는 심혈관 과학 자문 위원회 (CV SAB)의 구성을 발표하였습니다. 이 저명한 전문가 위원회는 투말린의 심혈관 질환 치료제인 파시베키투그의 개발을 위한 전략적 지침을 제공할 것입니다. CV SAB는 투말린이 2025년에 3상 임상시험 준비에 대한 진행을 지원할 것으로 기대됩니다.
이 자문 위원회는 심혈관 의학, 임상 시험 설계 및 치료 혁신에 대한 광범위한 경험을 가진 학계 및 산업의 베테랑들로 구성되어 있습니다. 그들의 전문성은 투말린의 심혈관 프로그램의 전략적 방향을 수립하는 데 중요할 것이며, TRANQUILITY 2상 임상시험의 진행도 포함되어 있으며, 이에 대한 주요 데이터는 2025년 상반기에 발표될 예정입니다.
Tourmaline Bio, Inc. (NASDAQ: TRML) a annoncé la formation de son Conseil Scientifique Consultatif Cardiovasculaire (CV SAB). Ce conseil d'experts de premier plan fournira des orientations stratégiques pour le développement de pacibekitug, le traitement de Tourmaline pour les maladies cardiovasculaires. Le CV SAB devrait soutenir Tourmaline alors qu'elle progresse vers une préparation pour des essais cliniques de Phase 3 en 2025.
Le conseil consultatif est composé de vétérans académiques et industriels ayant une vaste expérience en médecine cardiovasculaire, en conception d'essais cliniques et en innovation thérapeutique. Leur expertise sera essentielle pour façonner l'orientation stratégique du programme cardiovasculaire de Tourmaline, y compris l'essai clinique de Phase 2 TRANQUILITY en cours, pour lequel des données préliminaires sont attendues dans la première moitié de 2025.
Tourmaline Bio, Inc. (NASDAQ: TRML) hat die Bildung seines Kardiovaskulären Wissenschaftlichen Beratungsausschusses (CV SAB) bekannt gegeben. Dieser Ausschuss führender Experten wird strategische Anleitung für die Entwicklung von pacibekitug, Tourmalines Behandlung für Herz-Kreislauf-Erkrankungen, bereitstellen. Es wird erwartet, dass das CV SAB Tourmaline unterstützen wird, während es sich auf eine potenzielle Bereitschaft für klinische Studien der Phase 3 im Jahr 2025 zubewegt.
Der Beratungsausschuss setzt sich aus akademischen und industriellen Experten mit umfangreicher Erfahrung in der kardiovaskulären Medizin, im Design klinischer Studien und in therapeutischen Innovationen zusammen. Ihr Fachwissen wird entscheidend sein, um die strategische Ausrichtung von Tourmalines kardiovaskulärem Programm zu gestalten, einschließlich der laufenden TRANQUILITY Phase 2 klinischen Studie, bei der die wichtigsten Daten in der ersten Hälfte des Jahres 2025 erwartet werden.
- Formation of a Cardiovascular Scientific Advisory Board with leading experts
- Potential advancement to Phase 3 clinical trials for pacibekitug in 2025
- Ongoing TRANQUILITY Phase 2 clinical trial with expected topline data in H1 2025
- None.
– Tourmaline assembles leading experts to support the development of pacibekitug for cardiovascular diseases –
– Cardiovascular Scientific Advisory Board expected to provide strategic guidance as Tourmaline advances pacibekitug towards potential Phase 3 clinical trial readiness in 2025 for the treatment of cardiovascular diseases –
NEW YORK, Oct. 08, 2024 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (Tourmaline) (NASDAQ: TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients with life-altering immune and inflammatory diseases, today announced the formation of its Cardiovascular Scientific Advisory Board (CV SAB). The CV SAB is expected to provide strategic guidance and expertise as Tourmaline advances its pacibekitug cardiovascular diseases program, including the TRANQUILITY Phase 2 clinical trial that commenced earlier this year and for which Tourmaline continues to expect topline data in the first half of 2025.
The CV SAB brings together academic and industry veterans with significant experience in cardiovascular medicine, clinical trial design and execution, and therapeutic innovation. Their insights and guidance are expected to be instrumental in shaping the strategic direction of Tourmaline’s cardiovascular program as the company prepares for Phase 3 clinical trial readiness in 2025, supporting efforts to redefine standards of care for high-risk cardiovascular disease patients.
Cardiovascular Scientific Advisory Board Members:
- Joshua Beckman, MD, MSc – UT Southwestern Medical Center
- Marc Bonaca, MD, MPH – University of Colorado, CPC Clinical Research
- Robin Choudhury, MA, DM, FRCP – University of Oxford
- Douglas L. Mann, MD – Washington University School of Medicine
- James Min, MD – Cleerly, Inc.
- Pradeep Natarajan, MD, MMSc – Massachusetts General Hospital
- Michael D. Shapiro, DO, MCR – Wake Forest University School of Medicine
- Michael Szarek, PhD – University of Colorado, CPC Clinical Research
“We are honored to welcome such a distinguished group of experts to our Cardiovascular Scientific Advisory Board,” said Emil deGoma, MD, Senior Vice President of Medical Research at Tourmaline. “The depth and breadth of their collective expertise across atherosclerotic cardiovascular disease (ASCVD), heart failure, vascular medicine, imaging, genetics, and biostatistics will be invaluable as we advance pacibekitug for cardiovascular diseases. A growing body of evidence continues to support the therapeutic potential of IL-6 inhibition in ASCVD and beyond.”
For more information about Tourmaline Bio and pacibekitug, please visit https://www.tourmalinebio.com.
About Tourmaline Bio
Tourmaline is a late-stage clinical biotechnology company driven by its mission to develop transformative medicines that dramatically improve the lives of patients with life-altering immune and inflammatory diseases. Tourmaline’s lead asset is pacibekitug (also referred to as TOUR006).
About Pacibekitug
Pacibekitug (also referred to as TOUR006) is a long-acting, fully-human, anti-IL-6 monoclonal antibody with best-in-class potential and differentiated properties including a naturally long half-life, low immunogenicity, and high binding affinity to IL-6. Pacibekitug has been previously studied in approximately 450 participants, including patients with autoimmune disorders, across six completed clinical trials. Tourmaline is developing pacibekitug in thyroid eye disease (TED) and atherosclerotic cardiovascular disease (ASCVD) as its first two indications, with additional diseases under consideration.
Cautionary Note Regarding Forward-Looking Statements
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements may be identified by words and phrases such as “believe,” “designed to,” “expect,” “may,” “plan,” “potential,” “will” and similar expressions, and are based on Tourmaline’s current beliefs and expectations. These forward-looking statements include expectations regarding the development and potential therapeutic benefits of pacibekitug; the timing of initiation, progress and results of Tourmaline’s current and future clinical trials for pacibekitug, including reporting of data therefrom; the timing of Phase 3 clinical trial readiness; and the timing and potential to expand pacibekitug into additional indications. These statements involve risks and uncertainties that could cause actual results to differ materially from those reflected in such statements. Risks and uncertainties that may cause actual results to differ materially include uncertainties inherent in the development of therapeutic product candidates, such as the risk that any one or more of Tourmaline’s current or future product candidates will not be successfully developed or commercialized; the risk of delay or cessation of any planned clinical trials of Tourmaline’s current or future product candidates; the risk that prior results, such as signals of safety, activity or durability of effect, observed from preclinical trials, will not be replicated or will not continue in ongoing or future studies or clinical trials involving Tourmaline’s current or future product candidates; the risk that Tourmaline’s current or future product candidates or procedures in connection with the administration thereof will not have the safety or efficacy profile that Tourmaline anticipates; risks regarding the accuracy of Tourmaline’s estimates of expenses, capital requirements and needs for additional financing; changes in expected or existing competition; changes in the regulatory environment; the uncertainties and timing of the regulatory approval process; unexpected litigation or other disputes; the impacts of macroeconomic conditions Tourmaline’s business, clinical trials and financial position; and other risks and uncertainties that are described in Tourmaline’s Quarterly Report on Form 10-Q filed with the U.S. Securities and Exchange Commission (“SEC”) on August 8, 2024 and other filings that Tourmaline makes with the SEC from time to time. Any forward-looking statements speak only as of the date of this press release and are based on information available to Tourmaline as of the date hereof, and Tourmaline assumes no obligation to, and does not intend to, update any forward-looking statements, whether as a result of new information, future events or otherwise.
Media Contact
Scient PR
Sarah Mishek
SMishek@ScientPR.com
Investor Contact
Meru Advisors
Lee M. Stern
lstern@meruadvisors.com
FAQ
What is the purpose of Tourmaline Bio's new Cardiovascular Scientific Advisory Board?
When does Tourmaline Bio (TRML) expect topline data from the TRANQUILITY Phase 2 trial?
What is pacibekitug being developed for by Tourmaline Bio (TRML)?
Who are some of the members of Tourmaline Bio's new Cardiovascular Scientific Advisory Board?
